Wednesday, July 8, 2026

Patent intelligence · US

US 9687448

Nucleic acid lipid particle formulations

granted A61KA61K31/713A61K9/0019A61K9/1272
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 11
Applicant portfolio 379
Patent details — US 9687448
Jurisdiction
US
Status
granted
Grant date
Jun 27, 2017
Expiration
Jun 22, 2037
Claims
7
CPC classes
A61K, A61K31/713, A61K9/0019, A61K9/1272
View on Google Patents ↗

Quick answer

US 9687448 (Nucleic acid lipid particle formulations) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jun 27, 2017. Expires Jun 22, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
7
CPC classes
A61K, A61K31/713, A61K9/0019, A61K9/1272, A61K9/1617, A61K9/1641

More from Alnylam Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12416006

    Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Expires Sep 11, 2045

    granted
  2. US 12404508

    Ketohexokinase (KHK) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Expires Aug 28, 2045

    granted
  3. US 12397013

    Extrahepatic delivery

    Alnylam Pharmaceuticals, Inc. · Expires Aug 21, 2045

    granted
  4. US 12385043

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  5. US 12385044

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Aug 7, 2045

    granted
  6. US 12378553

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 31, 2045

    granted
  7. US 12364762

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 17, 2045

    granted
  8. US 12350338

    Biodegradable lipids for the delivery of active agents

    Alnylam Pharmaceuticals, Inc. · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 9687448?

US 9687448 (Nucleic acid lipid particle formulations) is held by Alnylam Pharmaceuticals, Inc.. Status: granted. Granted Jun 27, 2017. Expires Jun 22, 2037 (11 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9687448?

Alnylam Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 379 pharmaceutical patents for this assignee.

When does US 9687448 expire?

Our index shows an expiration date of Jun 22, 2037 (11 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.